Результаты поиска

Developing a Preliminary Conceptual Framework for Guidelines on Inclusion of Patient Reported-Outcome Measures (PROMs) in Clinical Quality Registries.

PurposePatient-centred and value-based health-care organisations are increasingly recognising the importance of the patient perspective in the measurement and evaluation of health outcomes. This has been primarily implemented using patient-reported outcome measures (PROMs). Clinical quality registries (CQRs) are specifically designed to improve direct clinical care, benchmark health-care provision and inform health service planning and policy. Despite CQRs having incorporated the patient perspective to support the evaluation of health-care provision, no evidence-based guidelines for inclusion

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.

BackgroundWe have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice.MethodsA total of 344 patients treated with IRD (N = 127) or RD (N = 217) were selected for analysis from the Czech Registry of Monoclonal Gammopathies (RMG). Descriptive statistics were used to assess patient's characteristics associated with the respective therapy. The primary endpoint was progression free survival (PFS

Факторы риска, связанные с позитивом и смертностью в связи с инфекциями в крови: Демографическое исследование пациентов с злокачественными заболеваниями B-Cell.

Заражение крови остается одной из основных причин смертности больных раком. Ключевое значение для совершенствования управления имеют инструменты наблюдения за патогенами и стратификации рисков. В настоящем исследовании описываются тенденции в области причинно-следственных патогенов и анализируются факторы риска для позитивной культуры крови (КМС) и послезаразной смертности у раковых больных. Мы провели когортное исследование пациентов с диагнозом " В-клеток " в регионе Северной Дании в период между 2013 и 2022, увязка данных о раковых заболеваниях с данными о состоянии здоровья. Были

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis.

OBJECTIVES: The coronavirus disease 2019 (COVID-19) pandemic has prompted many initiatives to identify safe and efficacious treatments, yet little is known regarding where early efforts have focused. We aimed to characterise registered clinical trials assessing drugs or plasma treatments for COVID-19. DESIGN, SETTING AND PARTICIPANTS: Cross-sectional analysis of clinical trials for the treatment of COVID-19 that were registered in the USA or in countries contributing to the WHO's International Clinical Trials Registry Platform. Relevant trial entries of drugs or plasma were downloaded on 26 M

Real-world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore.

Multiple myeloma, a hematological malignancy, imposes a significant financial burden on healthcare systems. Health technology assessments (HTA) and economic evaluations play vital roles in reimbursement decisions and cost containment. This study aimed to explore healthcare utilization patterns and costs among myeloma patients in Singapore through a retrospective analysis of 605 patients treated at two cancer centers. Data encompassing demographics, treatment utilization, and billing were extracted from electronic records, and a cost analysis was performed from the perspective of the Singapore

Использование стационарной гемато-онкологической службы до, во время и после COVID-19 Ограничения в румынском Третичном центре.

Введение Болезнь коронавируса 2019 (В тыс.COVID-19) пандемия помешала диагностике и лечению рака, однако имеющиеся в больницах данные об использовании стационарного гемато-онкологического обслуживания в Восточной Европе остаются ограниченными. В ходе этого исследования была проведена оценка того, как период пандемии повлиял на улавливание, диагностическое подтверждение, повторное стационарное лечение, госпитализацию и больничные дни среди взрослых с лимфомой, лейкемией или множественными миеломой в румынском высшем центре. В больнице скорой помощи округа Сибиу, Сибиу, Румыния, был проведен рет

Cost-effectiveness Analysis of Nutrition Facts Added-Sugar Labeling and Obesity-Associated Cancer Rates in the US.

ImportanceObesity-associated cancer burdens are increasing in the US. Nutrition policies, such as the Nutrition Facts added-sugar labeling, may reduce obesity-associated cancer rates.ObjectiveTo evaluate the cost-effectiveness of Nutrition Facts added-sugar labeling and obesity-associated cancer rates in the US.Design, setting, and participantsA probabilistic cohort state-transition model was used to conduct an economic evaluation of added-sugar labeling and 13 obesity-associated cancers among 235 million adults aged 20 years or older by age, sex, and race/ethnicity over a median follow-up of

Совпадение в полном тексте источника
… Cancer statistics a | Cancer incidence and survival | eAppendixes 1 and 2 in the Supplement | β | Stratified by age, sex, and race/ethnicity | NCI’s Surveillance, Epidemiology, and End Results Program Database; CDC’s National Program of Cancer Registries Database 1 6. … Program of Cancer Registries and the Surveillance, Epidemiology, and End Results program. 27 We projected the cancer incidence from 2015 to 2030 based on the incidence of cancer from 2006 to 2014 using the average annual percent change method (eAppendix 1 in the Supplement ). 14 We extracted and converted …

Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (BMT).

Allogeneic Blood and Marrow Transplant (BMT) survivors are at high risk of secondary cancers. Although current guidelines endorse survivors following Country-specific general population screening recommendations to mitigate this risk, little is known about cancer screening adherence in Australian BMT survivors. We conducted a cross-sectional survey of 441 BMT survivors who were >1 year post transplant, to explore rates of screening for secondary cancers and to identify barriers to cancer screening recommendations. Survey instruments included the Sydney Post-BMT Survey, FACT-BMT, DASS 21, The C

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

BackgroundThere has been an increase in 'risk sharing' schemes for pharmaceuticals between healthcare institutions and pharmaceutical companies in Europe in recent years as an additional approach to provide continued comprehensive and equitable healthcare. There is though confusion surrounding the terminology as well as concerns with existing schemes.MethodsA literature review was undertaken to identify existing schemes supplemented with additional internal documents or web-based references known to the authors. This was combined with the extensive knowledge of health authority personnel from

Демографическое исследование тенденций заболеваемости миеломой в Соединенных Штатах 2000-2020.

Миэлома one из наиболее распространенных видов гематологических магнатов. Мы намеревались изучить показатели распространенности миеломы в разбивке по полу, расе, возрасту и гистологическим подгруппам в Соединенных Штатах (США) в целом. 2000-2020. Данные были получены из системы наблюдения, эпидемиологии и конечных результатов (SEER) 22 База данных. Вариант Международной классификации болезней для онкологии 3 морфологические коды 9731, 9732, и 9734 Они были назначены для одиночной плазмоцитомы кости, плазменной клеточной миеломы и излишней плазмоцитомы, соответственно. Сообщалось о среднегодово

Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.

The landscape of treatment for multiple myeloma (MM) has significantly changed over the last decade due to novel agents that have shown superiority in efficacy such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) over traditional therapies. However, the real-world utilization of these new agents has not been studied well. This study evaluated year-to-year changes in treatment choices in a cohort of patients aged 66 or older in the Surveillance, Epidemiology, and End Results (SEER) registry linked with Medicare claims (SEER-Medicare) data who were diagnosed with MM between 200

Reframing disease burden: validation of DALY-per-case as a per-diagnosis severity metric.

BACKGROUND: Population-weighted metrics (incidence, mortality, disability-adjusted life years (DALYs), mortality to incidence ratio (MIR) can obscure per-case severity for less prevalent but high-impact conditions. This paper introduces DALY per case, total DALYs divided by incident cases, as a standardized estimate of healthy life-years lost per new diagnosis, integrating years of life lost (YLL) and years lived with disability (YLD). Validated using cancers and applied across diverse diseases, the metric enables prevalence-independent severity comparisons. METHODS: Using GBD 2021, we comput

Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.

AbstractThere has been an increase in volume as well as an improvement in overall survival (OS) after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if these changes have affected racial/ethnic minorities equally. In this observational study from the Center for International Blood and Marrow Transplant Research of 79 904 autologous (auto) and 65 662 allogeneic (allo) HCTs, we examined the volume and rates of change of autoHCT and alloHCT over time and trends in OS in 4 racial/ethnic groups: non-Hispanic Whites (NHWs), non-Hispanic African Americans (NHAAs), a

Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Role of remdesivir for the treatment of COVID-19 in patients with hematologic malignancy-A narrative review and expert opinion.

BackgroundCOVID-19 remains a potentially severe condition for immunocompromised individuals, such as patients with hematologic malignancy. These patients are at increased risk of progressing to severe-critical or prolonged COVID-19. Prompt treatment with antivirals has proven effective in preventing disease progression and is recommended by current guidelines. We discuss here the position of remdesivir in the management of onco-hematologic patients infected with SARS-CoV-2 and strategies for its use.MethodsNarrative review of current evidence regarding remdesivir in the treatment of COVID-19 i

Global Panoramic analysis of clinical research in cell therapy: clinical trial landscape, marketed products, and regulatory trends.

IntroductionCell therapy is a vital field in modern medicine. This review assesses its global clinical development landscape, approved products, and regional regulatory characteristics.MethodsA comprehensive search and analysis of global clinical trial databases (e.g., https://clinicaltrials.gov/ClinicalTrials.gov), regulatory agency announcements, and relevant literature up to October 2025 was conducted. Key data points regarding trial numbers, phases, therapy types, and approved products were extracted and analyzed descriptively by region.ResultsA cumulative total of 10,373 cell therapy clin

Global Burden of Rare Cancers: Insights from GLOBOCAN 2022 Estimates.

Background: Rare cancers, defined as those with an incidence rate of fewer than 6 cases per 100,000 individuals, contribute to a substantial portion of the global cancer burden. Despite their impact, they receive less attention than more common malignancies, leading to challenges in early detection, treatment strategies, and research funding. This study aims to assess the global incidence and mortality patterns of rare cancers in 2022 to better understand their contribution to the overall cancer burden and regional disparities. Methods: We conducted a comprehensive analysis using 2022 GLOBOCAN

Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview.

The practical aspects of developing curative treatments for sickle cell disease (SCD) in Africa, such as gene therapy and hematopoietic stem cell transplantation, involve strengthening healthcare infrastructure, training healthcare professionals, establishing regional treatment centers, and creating national SCD programs. The costs associated with gene therapy and stem cell transplants can be prohibitive, especially in low- and middle-income countries. Strategies to address affordability, including local manufacturing, government funding, and partnerships with global health agencies, are essen

Association of Metabolic Parameter Variability with Esophageal Cancer Risk: A Nationwide Population-Based Study.

Introduction: Certain metabolic parameters increase the risk of esophageal cancer. This study investigated the association between the variability in metabolic parameters and esophageal cancer incidence using large nationally representative data. Methods: Using the health checkup and claims data provided by the Korean National Health Insurance Service (NHIS), we included 8,376,233 subjects who underwent NHIS-provided health checkups between 2009 and 2010 (index year) and two or more health checkups within five years before the index year. Hazard ratios (HRs) and 95% confidence intervals (CIs)

Резюме, представленные на 32nd Ежегодная конференция Международного общества по изучению качества жизни.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.